vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and RENAISSANCERE HOLDINGS LTD (RNR). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.2B, roughly 1.3× RENAISSANCERE HOLDINGS LTD). RENAISSANCERE HOLDINGS LTD runs the higher net margin — 23.5% vs -3.7%, a 27.2% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -36.8%). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -11.9%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
RenaissanceRe Holdings Ltd is a Bermudian provider of reinsurance, insurance and other related business services. The company operates in reinsurance, insurance and ventures.
BHC vs RNR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.2B |
| Net Profit | $-103.0M | $515.8M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | — |
| Net Margin | -3.7% | 23.5% |
| Revenue YoY | 9.3% | -36.8% |
| Net Profit YoY | -205.1% | 72.6% |
| EPS (diluted) | $-0.30 | $6.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.2B | ||
| Q4 25 | $2.8B | $3.0B | ||
| Q3 25 | $2.7B | $3.2B | ||
| Q2 25 | $2.5B | $3.2B | ||
| Q1 25 | $2.3B | $3.5B | ||
| Q4 24 | $2.6B | $2.3B | ||
| Q3 24 | $2.5B | $4.0B | ||
| Q2 24 | $2.4B | $2.8B |
| Q1 26 | — | $515.8M | ||
| Q4 25 | $-103.0M | $760.5M | ||
| Q3 25 | $179.0M | $916.5M | ||
| Q2 25 | $148.0M | $835.4M | ||
| Q1 25 | $-58.0M | $170.0M | ||
| Q4 24 | $98.0M | $-189.7M | ||
| Q3 24 | $-85.0M | $1.2B | ||
| Q2 24 | $10.0M | $503.9M |
| Q1 26 | — | — | ||
| Q4 25 | 17.0% | 42.5% | ||
| Q3 25 | 23.1% | 46.3% | ||
| Q2 25 | 17.5% | 41.8% | ||
| Q1 25 | 12.2% | -2.0% | ||
| Q4 24 | 21.8% | -3.6% | ||
| Q3 24 | 12.7% | 43.7% | ||
| Q2 24 | 16.2% | 25.0% |
| Q1 26 | — | 23.5% | ||
| Q4 25 | -3.7% | 25.6% | ||
| Q3 25 | 6.7% | 28.7% | ||
| Q2 25 | 5.8% | 26.1% | ||
| Q1 25 | -2.6% | 4.9% | ||
| Q4 24 | 3.8% | -8.3% | ||
| Q3 24 | -3.4% | 29.8% | ||
| Q2 24 | 0.4% | 17.8% |
| Q1 26 | — | $6.57 | ||
| Q4 25 | $-0.30 | $16.16 | ||
| Q3 25 | $0.48 | $19.40 | ||
| Q2 25 | $0.40 | $17.20 | ||
| Q1 25 | $-0.16 | $3.27 | ||
| Q4 24 | $0.24 | $-3.76 | ||
| Q3 24 | $-0.23 | $22.62 | ||
| Q2 24 | $0.03 | $9.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $1.6B |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $4.3B |
| Total Assets | $26.4B | $53.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $719.0M | $1.6B | ||
| Q2 24 | $595.0M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $20.8B | $2.3B | ||
| Q3 25 | $21.0B | $2.2B | ||
| Q2 25 | $21.7B | $2.3B | ||
| Q1 25 | $21.5B | $2.8B | ||
| Q4 24 | $21.6B | $1.9B | ||
| Q3 24 | $21.5B | $1.9B | ||
| Q2 24 | $21.7B | $2.0B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $-554.0M | $11.6B | ||
| Q3 25 | $-565.0M | $11.5B | ||
| Q2 25 | $-764.0M | $10.8B | ||
| Q1 25 | $-1.2B | $10.3B | ||
| Q4 24 | $-1.3B | $10.6B | ||
| Q3 24 | $-1.2B | $11.2B | ||
| Q2 24 | $-1.2B | $10.2B |
| Q1 26 | — | $53.7B | ||
| Q4 25 | $26.4B | $53.8B | ||
| Q3 25 | $26.8B | $54.5B | ||
| Q2 25 | $27.3B | $54.7B | ||
| Q1 25 | $26.4B | $53.6B | ||
| Q4 24 | $26.5B | $50.7B | ||
| Q3 24 | $26.5B | $52.8B | ||
| Q2 24 | $26.5B | $51.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | — |
| Free Cash FlowOCF − Capex | $403.0M | — |
| FCF MarginFCF / Revenue | 14.4% | — |
| Capex IntensityCapex / Revenue | 3.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $495.0M | $483.0M | ||
| Q3 25 | $405.0M | $1.6B | ||
| Q2 25 | $289.0M | $1.5B | ||
| Q1 25 | $211.0M | $157.8M | ||
| Q4 24 | $601.0M | $778.9M | ||
| Q3 24 | $405.0M | $1.5B | ||
| Q2 24 | $380.0M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $403.0M | — | ||
| Q3 25 | $314.0M | — | ||
| Q2 25 | $190.0M | — | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $495.0M | — | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 14.4% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.64× | ||
| Q3 25 | 2.26× | 1.73× | ||
| Q2 25 | 1.95× | 1.76× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | 38.00× | 2.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
RNR
Segment breakdown not available.
